Expert Interview
Interpreting both Alkermes’ ALKS-2680 and Takeda’s TAK-861 initial data for narcolepsy and how the OX2R class may ultimately fit in the treatment paradigm
Ticker(s): ALKS, TAK, CNTAInstitution: Johns Hopkins
- Medical Director, Johns Hopkins Sleep Disorders Center and Associate Professor of Neurology at JHU School of Medicine.
- Actively treats over 1,500 patients with OSA, 20-30 patients with Narcolepsy, and 40-50 patients with Idiopathic Hypersomnia.
- Research interests are in the area of sleep medicine, specifically investigating the co-morbid health consequences of chronic sleep deprivation.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
